Advertisement.
Advertisement.
Advertisement
Advertisement.
VOR Vor Biopharma Inc
468
| Market Cap | $64.96M |
| Volume | 194,517.00 |
| 52-Wk High | $3.18 |
| 52-Wk Low | $0.90 |
Vor Bio to Participate in Upcoming Investor Conferences
Globe Newswire•4 months ago
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Share to Feed
Vor Biopharma GAAP EPS of -$0.39 beats by $0.11...
SeekingAlpha.com: All News•4 months ago
Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024VCAR33ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into...
Globe Newswire•4 months ago
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of March 1, 2024, the...
Globe Newswire•5 months ago
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Globe Newswire•5 months ago
JonesTrading analyst Justin Walsh maintained a Buy rating on Vor Biopharma (VOR Research Report) today and set a price target of $18.00. Justin W...
TipRanks Financial Blog•6 months ago
CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of January 29, 2024, the...
Globe Newswire•6 months ago
First patient dosed in company's second clinical program with initial data expected in second half of 2024Cash runway extended into second half of 2025 with clinical trials on track CAMBRIDGE...
Globe Newswire•6 months ago